Portland, Ore. (August 5, 2019)—The National Psoriasis Foundation, NPF, has appointed three experts highly regarded for their work in the psoriatic disease community to its medical board. The addition of these leaders complements the 28 other board members clinical and scientific expertise and perspective in both psoriasis and psoriatic arthritis. New board members include:
April Armstrong, M.D., MPH Dr. Armstrong is professor of Dermatology, associate dean and vice-chair in the dermatology department at the University of Southern California. Appointed to the medical board for a second time, Dr. Armstrong will be the principal investigator for NPF’s Citizen Pscientist validation, Treat to Target study and will be a key contributor on other initiatives as well.
George Han, M.D., Ph.D. Dr. Han is the system medical director for Dermatology and chief of Teledermatology, Icahn School of Medicine at Mount Sinai. Recognized as an accomplished dermatologist focused on helping educate both patients and health care providers on treating psoriasis, Dr. Han will chair NPF’s Grand Rounds program which targets communities, rural and/or underserved areas of the country where access to dermatologic care is limited and will help expand the Foundation’s continuing medical education programs for healthcare professionals.
Jason Ezra Hawkes, M.D., M.S. A board-certified dermatologist, and physician-scientist, Dr. Hawkes is chief clinical scholar and instructor in Clinical Investigation, Laboratory for Investigative Dermatology at The Rockefeller University. Bringing both clinical experience and educational expertise, Dr. Hawkes will be a co-chair of NPF’s annual Residents Meeting and will be involved with a new program which will strive to provide psoriasis and psoriatic arthritis educational materials that can be incorporated into medical school curricula nationwide.
The NPF medical board provides guidance and leadership to the organization on all medical issues related to the psoriatic disease community. The board also facilitates access to quality care by advocating for better clinical research tools, promoting medical education, and identifying and promoting medical professionals who most effectively treat psoriatic disease.